# Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

> **NCT00810602** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pavan Reddy, MD** · enrollment: 61 (actual)

## Conditions studied

- Hematologic Malignancies
- Graft vs Host Disease

## Interventions

- **PROCEDURE:** reduced intensity, related donor stem cell transplant
- **DRUG:** tacrolimus (standard GVHD prophylaxis)
- **DRUG:** mycophenolate (standard GVHD prophylaxis)
- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT00810602
- **Lead sponsor:** Pavan Reddy, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-07
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810602, "Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00810602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*